Bottom line
IYH vs HGHAX: the short answer
IYH (iShares U.S. Healthcare ETF) and HGHAX (The Hartford Healthcare Fund) share a meaningful slice of their top holdings — about 68% by weight.
IYH is cheaper at 0.37% vs 1.33% — a difference of $96 a year per $10,000 invested.
HGHAX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
IYH vs HGHAX side by side
| IYH | HGHAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Hartford |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.37% | 1.33% |
| Annual cost per $10k | $37 | $133 |
| 10-yr cost on $10k (prospectus) | $468 | $2,063 |
| Max front load | None | 5.5% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +13.1% | — |
| 5-yr return (annualized) | +7.0% | — |
| 10-yr return (annualized) | +9.4% | — |
| Best quarter | +15.3% | +20.9% |
| Worst quarter | −12.7% | −15.7% |
| Net assets (fund) | $3.6B | $772.2M |
| Number of holdings | 103 | 80 |
| Portfolio turnover | 3% | 49% |
| Returns as of | Dec 31, 2025 | — |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IYH | HGHAX | Difference |
|---|---|---|---|
| 2025 | +13.1% | +15.6% | −2.5% |
| 2024 | +3.1% | 0.0% | +3.1% |
| 2023 | +2.1% | +3.8% | −1.7% |
| 2022 | −4.4% | −11.7% | +7.4% |
| 2021 | +23.4% | +10.0% | +13.4% |
| 2020 | +15.5% | +22.6% | −7.1% |
| 2019 | +20.8% | +33.3% | −12.5% |
| 2018 | +5.9% | −3.0% | +8.9% |
| 2017 | +22.3% | +21.6% | +0.7% |
| 2016 | −2.8% | −8.6% | +5.8% |
Source: Fund prospectus bar charts
Holdings overlap
17 of IYH's top 25 holdings also appear in HGHAX's top 25.
| Holding | IYH | HGHAX |
|---|---|---|
| Eli Lilly And Company | 15.11% | 12.03% |
| Johnson & Johnson | 10.17% | 6.75% |
| Abbvie Inc. | 7.32% | 4.21% |
| Unitedhealth Group Incorporated | 6.16% | 4.74% |
| Merck & Co., Inc. | 5.31% | 6.00% |
| Thermo Fisher Scientific Incorporated | 3.52% | 1.58% |
| Amgen Inc. | 3.42% | 1.39% |
| Abbott Laboratories | 3.02% | 1.82% |
| Intuitive Surgical, Inc. | 2.05% | 2.88% |
| Danaher Corporation | 2.03% | 2.57% |
| Vertex Pharmaceuticals Incorporated | 2.00% | 2.64% |
| Stryker Corporation | 1.86% | 1.24% |
| Elevance Health, Inc. | 1.34% | 3.00% |
| Regeneron Pharmaceuticals, Inc. | 1.27% | 2.02% |
| Boston Scientific Corporation | 1.14% | 1.88% |
Source: SEC Form N-PORT
IYH top 10
- Eli Lilly And Company — 15.11%
- Johnson & Johnson — 10.17%
- Abbvie Inc. — 7.32%
- Unitedhealth Group Incorporated — 6.16%
- Merck & Co., Inc. — 5.31%
- Thermo Fisher Scientific Incorporated — 3.52%
- Amgen Inc. — 3.42%
- Abbott Laboratories — 3.02%
- Gilead Sciences, Inc. — 2.66%
- Pfizer Inc. — 2.35%
HGHAX top 10
- Eli Lilly & Co — 12.03%
- Johnson & Johnson — 6.75%
- Merck & Co Inc — 6.00%
- UnitedHealth Group Inc — 4.74%
- AbbVie Inc — 4.21%
- Elevance Health Inc — 3.00%
- Intuitive Surgical Inc — 2.88%
- CVS Health Corp — 2.84%
- Vertex Pharmaceuticals Inc — 2.64%
- Danaher Corp — 2.57%
FAQ
What is the difference between IYH and HGHAX?
Which is cheaper, IYH or HGHAX?
Should I own both IYH and HGHAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.